Cardiovascular Agent

The following article is from The Great Soviet Encyclopedia (1979). It might be outdated or ideologically biased.

Cardiovascular Agent


a medicinal preparation used in the treatment of heart failure and disorders of vascular tension. Cardiovascular agents include cardiac glycosides, vasodilators, and vasoconstrictors. Most cardiac glycosides and digitalis glycosides are similar in structure and activity; they differ primarily in side effects, the speed and duration of activity, and the tendency toward cumulation.

Cardiovascular agents increase the force and reduce the frequency of cardiac contractions; they also improve metabolism in cardiac muscular tissue. They are used under medical supervision in cases of heart failure and abnormal cardiac rhythm (for example, in treating the tachyarrhythmic form of atrial fibrillation and the supraventricular form of paroxysmal tachycardia).

The most effective cardiovascular agents are digitalis powder, tincture, and extract, as well as such secondary digitalis glycosides as digitoxin and digoxin. Also effective are preparations containing a combination of glycosides (for example, lanatosides) and preparations of Strophantus, Adonis (for example, adonisid), Convallaria (for example, corglykon), and Erisimum (for example, erisimin).

Vasodilators relax the smooth musculature of the coronary and peripheral arteries and reduce vasospasms. For example, an attack of angina pectoris is arrested by the use of such quick-acting vasodilators as nitroglycerin and amyl nitrite. Attacks are prevented during chronic coronary insufficiency by the administration of Euphyllin, papaverine, and vasodilators with long-term action, such as pentacrythrityl tetranitrate and sustac.

Many preparations, for example, chromonar (Intensain), not only strengthen coronary blood flow but also improve metabolic processes in the heart, reduce the oxygen requirement of the myocardium, and strengthen collateral circulation. Propranolol (Inderal), a β-adrenergic blocking agent, simultaneously improves metabolic processes in the heart and reduces the contractile activity of the myocardium. Pyridinol carbamate (anginine) improves microcirculation.

Medicinal treatments for injuries to peripheral arteries include the application of vasodilators and substances that stimulate the formation of collaterals and improve microcirculation. Preparations that excite the vasomotor center, for example, cardiamin, corazole, and camphor, are prescribed in cases of vascular insufficiency accompanied by hypotonia. In cases of acute vascular insufficiency (collapse), quick-acting vasoconstrictors, such as noradrenaline, phenylephrine hydrochloride, and angiotensin amide, are administered.


Votchal, B. E., and M. E. Slutskii. Serdechnye glikozidy. Moscow, 1973.
Glezer, G. A. Spravochnik po farmakoterapii serdechno-sosudistykh zabolevanii. Moscow, 1974.


The Great Soviet Encyclopedia, 3rd Edition (1970-1979). © 2010 The Gale Group, Inc. All rights reserved.
References in periodicals archive ?
Among adults age 65 and over, 70.2% took at least one cardiovascular agent and 46.7% took a cholesterol-lowering drug in the past 30 days in 2007-2010.
Created in 1986, the JV had exclusive rights to make and distribute Sanofia[euro](tm)s cardiovascular agent Milrila (milrinone) and had entrusted Astellas to produce and market the drug.
In specific, we found dual eligibility enrollment to be associated with a lower likelihood of noncompliance with cardiovascular agent use for each therapeutic class we studied.
Warner-Lambert: Key Pharmaceutical Products PRODUCT CATEGORY SALES (000) Lipitor [*] Cholesterol lowering $3,732 Neurontin Seizure disorders 913 Rezulin Diabetes 625 Viracept AIDS 530 Accupril Cardiovascular agent 514 (*.)Copromoted with Pfizer Inc.
Sankyo Parke Davis, a joint venture formed last year, is copromoting Rezulin and the cardiovascular agent Accupril with Parke-Davis.
The company's pharmaceutical business remains strong despite the patent expiration of its Capoten cardiovascular agent in 1996.
Calcium channel blockers are responsible for more cardiovascular fatalities than any other cardiovascular agents in the USA, with an estimated 35% mortality rate.
These include neuroleptics, cardiovascular agents, analgesics, antiallergic, anti-epileptics, anxiolytics, sedatives, hypnotics, diuretics, anti-parkinsonism agents, anti-bacterial agents and drugs used for erectile dysfunction.23-25 The research is still going on.
There are two new cardiovascular agents. Ivabradine (Corlanor) is a hyperpolarization-activated cyclic nucleotide-gated channel blocker that is indicated to reduce the risk of hospitalization for worsening heart failure.
Adverse drug events occurred in 47% of patients on cardiovascular agents other than diuretics, 21% of patients on diuretics, and 5% of patients on opioids.
Antidepressants' potential for drug interactions is especially important for patients who take > 1 other medication, including cardiovascular agents. (1)

Full browser ?